TheraCell is a US-based biomedical products company, and a wholly-owned subsidiary of Titan Pharmaceuticals, Inc.
The licensed technology includes a biologically compatible, oxygenated gel that improves bone regeneration and fusion of bone grafts. The technology will be used in conjunction with TheraCell's proprietary scaffold technology for enhancing the efficiency of spinal fusion procedures.
In addition, the licensing agreement includes novel methods for purifying and manipulating stem cells derived from patients.
Deal Type Partnership Sub-Category Licensing Agreement Deal Status Announced: 2009-07-14
Deal Participants
Partner 1 (Company) Yissum Research Development Company Partner 2 (Company) The Hebrew University of Jerusalem Partner 3 (Company) TheraCell, Inc. Partner 4 (Company) Titan Pharmaceuticals, Inc.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index